SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) Meeting Abstract
| Authors: | Rudin, C. M.; Liu, S. V.; Lu, S.; Soo, R. A.; Hong, M. H.; Lee, J. S.; Bryl, M.; Dumoulin, D. W.; Rittmeyer, A.; Chiu, C. H.; Ozyilkan, O.; Navarro, A.; Novello, S.; Ozawa, Y.; Meng, R.; Hoang, T.; Lee, A.; Wen, X.; Huang, M.; Reck, M. |
| Abstract Title: | SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-10 |
| Language: | English |
| ACCESSION: | WOS:000891791500033 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.17_suppl.LBA8507 |
| Notes: | Meeting Abstract: LBA8507 -- Source: Wos |
